Table 2.

Tumour responses in enrolled patients and patients based on prior anti- vascular endothelial growth factor therapies. CR, complete response; PR, partial response; SD, stable disease; PD, progress disease; VEGF, vascular endothelial growth factor.

	No. (%)	Best response cycles Median (Range)	Ever prior anti-VEGF No. (%)	Never prior anti-VEGF No. (%)	P value
Total	48	4.0 (1–14)	15 (31.2)	33 (68.8)
CR	0 (0)	0 (0)	0 (0)	0 (0)
PR	4 (8.3)	7.5 (5–14)	2 (13.3)	2 (6.1)
SD	29 (60.4)	4.0 (1–11)	7 (26.7)	22 (67.7)
PD	8 (16.7)		3 (20)	5 (15.2)
Missing efficacy	7 (14.6)		3 (20)	4 (12.1)
Overall response	4 (8.3)		2 (13.3)	2 (6.1)	0.50
Disease control	33 (68.7)		9 (60)	24 (72.7)	0.66